A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors (Q34488671)
Jump to navigation
Jump to search
scientific article published on November 8, 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors |
scientific article published on November 8, 2010 |
Statements
1 reference
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors (English)
1 reference
A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors (English)
1 reference
Frank M. Balis
Richard Aplenc
1 reference
Elizabeth Fox
1 reference
Rochelle Bagatell
1 reference
Eva Dombi
1 reference
Wendy Goodspeed
1 reference
Anne Goodwin
1 reference
Marie Kromplewski
1 reference
Nalini Jayaprakash
1 reference
Marcelo Marotti
1 reference
Barbara Wenrich
1 reference
Meredith K. Chuk
Kathryn H. Brown
Peter C. Adamson
Brigitte C. Widemann
8 November 2010
1 reference
1 reference
28
1 reference
35
1 reference
5174-5181
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference